miR-6850 drives phenotypic changes and signaling in high grade serous ovarian cancer.

Kamil Filipek, Daniela Pollutri, Ivana Kurelac, Giuseppe Gasparre, Marianna Penzo

Abstract read

In one paragraph

Article in Non-coding RNA research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kamil FilipekDepartment of Medical and Surgical Sciences and Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum University of Bologna, Italy.

Daniela PollutriDepartment of Medical and Surgical Sciences and Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum University of Bologna, Italy.

Ivana KurelacDepartment of Medical and Surgical Sciences and Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum University of Bologna, Italy.

Giuseppe GasparreDepartment of Medical and Surgical Sciences and Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum University of Bologna, Italy.

Marianna PenzoDepartment of Medical and Surgical Sciences and Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum University of Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression, and their dysregulation is closely linked to cancer development. Ovarian cancer (OC), particularly the high-grade serous ovarian carcinoma (HGSOC) subtype, is the most lethal gynecological malignancy, primarily due to late-stage diagnosis and limited treatment options. Among the miRNAs encoded at the often amplified 8q24.3 region, miR-6850 has emerged as a potential candidate target owing to its genomic positioning inside this hotspot and its unexpectedly low expression in HGSOC tissues and cell lines. In silico investigations indicated that, despite the gain in MIR6850 copy number, its mature products, miR-6850-5p and miR-6850-3p, were expressed at low levels; notably,

Indexed as

EMTmiRNANIH:OVCAR3Ovarian cancerProtein synthesisSKOV-3

Identifiers

PMID41282576

DOI10.1016/j.ncrna.2025.10.004

PMCPMC12636381

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.